NY-ESO-1 (CTAG1B) expression in mesenchymal tumors

Makoto Endo, Marieke A. De Graaff, Davis R. Ingram, Simin Lim, Dina C. Lev, Inge H. Briaire-De Bruijn, Neeta Somaiah, Judith V.M.G. Bovée, Alexander J. Lazar, Torsten O. Nielsen

Research output: Contribution to journalArticlepeer-review

60 Citations (Scopus)


New York esophageal squamous cell carcinoma 1 (NY-ESO-1, CTAG1B) is a cancer-testis antigen and currently a focus of several targeted immunotherapeutic strategies. We performed a large-scale immunohistochemical expression study of NY-ESO-1 using tissue microarrays of mesenchymal tumors from three institutions in an international collaboration. A total of 1132 intermediate and malignant and 175 benign mesenchymal lesions were enrolled in this study. Immunohistochemical staining was performed on tissue microarrays using a monoclonal antibody for NY-ESO-1. Among mesenchymal tumors, myxoid liposarcomas showed the highest positivity for NY-ESO-1 (88%), followed by synovial sarcomas (49%), myxofibrosarcomas (35%), and conventional chondrosarcomas (28%). Positivity of NY-ESO-1 in the remaining mesenchymal tumors was consistently low, and no immunoreactivity was observed in benign mesenchymal lesions. On the basis of these findings, nearly 90% of myxoid liposarcomas, as well as a significant proportion of synovial sarcomas, myxofibrosarcomas, and conventional chondrosarcomas are good candidates for immunotherapy targeting NY-ESO-1.

Original languageEnglish
Pages (from-to)587-595
Number of pages9
JournalModern Pathology
Issue number4
Publication statusPublished - Apr 8 2015

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine


Dive into the research topics of 'NY-ESO-1 (CTAG1B) expression in mesenchymal tumors'. Together they form a unique fingerprint.

Cite this